

Statement of Deficiencies	(X1) Provider/Supplier/CLIA Identification Number 17D0453242	(X3) Date Survey Completed 05/04/2023
Name of Provider or Supplier Minneola District Hospital	Street Address, City, State 212 Main Street, Minneola, KS	
For information on the provider's plan to correct this deficiency, please contact the provider or the state survey agency.		

(X4) ID Prefix Tag	Summary Statement of Deficiencies
D2016	<p>SUCCESSFUL PARTICIPATION CFR(s): 493.803(a)(b)(c)</p> <p>(a) Each laboratory performing nonwaived testing must successfully participate in a proficiency testing program approved by CMS, if applicable, as described in subpart I of this part for each specialty, subspecialty, and analyte or test in which the laboratory is certified under CLIA. (b) Except as specified in paragraph (c) of this section, if a laboratory fails to participate successfully in proficiency testing for a given specialty, subspecialty, analyte or test, as defined in this section, or fails to take remedial action when an individual fails gynecologic cytology, CMS imposes sanctions, as specified in subpart R of this part. (c) If a laboratory fails to perform successfully in a CMS-approved proficiency testing program, for the initial unsuccessful performance, CMS may direct the laboratory to undertake training of its personnel or to obtain technical assistance, or both, rather than imposing alternative or principle sanctions except when one or more of the following conditions exists: (1) There is immediate jeopardy to patient health and safety. (2) The laboratory fails to provide CMS or a CMS agent with satisfactory evidence that it has taken steps to correct the problem identified by the unsuccessful proficiency testing performance. (3) The laboratory has a poor compliance history.</p> <p>This CONDITION is not met as evidenced by: Based on the review of proficiency testing (PT) records from College of American Pathologists (CAP) and phone interview, the laboratory failed to successfully participate in PT for the analyte: 0595 Thyroxine (T4) for two consecutive proficiency testing events: 2022 Event 3 and 2023 Event 1 (refer to D2107).</p>
D2107	<p>ENDOCRINOLOGY CFR(s): 493.843(f)</p> <p>Failure to achieve satisfactory performance for the same analyte or test in two</p>

consecutive testing events or two out of three consecutive testing events is unsuccessful performance.

This STANDARD is not met as evidenced by:

Based on a desk review of proficiency testing (PT) records from the CMS report 0155D and phone interview, the laboratory failed to achieve satisfactory performance in PT for the regulated analyte 0595 Thyroxine (T4) for two consecutive testing events. Findings: 1. A review of proficiency testing records from the PT provider College of American Pathologists (CAP) Proficiency Testing for the regulated analyte 0595 Thyroxine (T4) revealed the following performance scores for the periods indicated: 2. Third testing event, 2022 revealed a score 0% 3. First testing event, 2023 revealed a score of 0% 4. Phone interview on May 4, 2023 at 2:45 p.m. confirmed, the laboratory failed to achieve satisfactory performance in PT for the regulated analyte Thyroxine (T4) for two consecutive testing events.